RESULTS
In nine of the eleven patients the platelet count rose to more than 100 X 109/l during 2-9 days, and reached its maximum between 4-12 days ( 1 ). Sustained elevation of platelet counts higher than 100 x 109/l had been observed in all splenectomized patients during two months following splenectomy (Fig. 1 ). In the "responder" group, patients 1 and ll refused to have the planned splenectomy. In patients 8 and 10 bolus mPSL was administered two and three times respectively because they also at first refused to have a planned splenectomy. The platelet counts in patients 8 and 10 increased by each treatment but the counts returned to their original levels during 3-4 weeks. The patients then agreed to a proposal for splenectomy, and a planned splenectomy was performed following the last bolus mPSL. 1 and ll during two months following bolus mPSL. In patient ll the dosage of mPSLwas gradually tapered because he had been treated with oral corticosteroid for five months beforehand. In patients 3 and 9 the platelet counts increased slightly but returned to their original levels within one month.
Side effects were observed in four of the eleven patients.
Hyperglycemia developed in three patients but was controlled well by insulin. Weight gain was observed in two patients.
DISCUSSION
Steroid therapy is effective in 70-80% of adult ITP cases. An increase in the platelet count usually occurs within 3-7 days, with a maximum response between 14-21 days . Corticosteroids are usually administered for 4-6 weeks because there is a small percentage of patients with a late response4^.
In bolus mPSL therapy improvement of platelet counts occurs within several days and peaks within ten days. It is noteworthy that bolus mPSL therapy was very effective even in patient 1, who did not respond to a previous steroid therapy. Response to bolus mPSL is more rapid than that of oral corticosteroids, and is very similar to i.v. intact immunoglobulin in adult ITP . We had no patients having a late response after bolus mPSL. Therefore, a planned splenectomy without a platelet transfusion is possible for those patients who respond. It is very favorable for young female pat ients. In addition, the cost for bolus mPSL therapy is 1/100 the cost ofi.v. intact immunoglobulin therapy in Japan. In two patients (patients 8 and 10) bolus mPSL therapy was performed two and three times respectively because: 1) they at first refused to have splenectomy and 2) the effect was temporary. This suggests that the sustained remission cannot be obtained with this therapy alone, in some patients, although a controlled study is required.
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